RSSDI Repository, Complications of Diabetes Demonstration RSSDI Repository, Complications of Diabetes Demonstration

Have a Question?

If you have any question you can ask below or enter what you are looking for!

  • Home/
  • Article /
  • Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial.

Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial.

Add to Collection
2019 Nov RCTs Fist_Author_Year_PM

Full Author : ['Lingvay, Ildiko', 'Catarig, Andrei-Mircea', 'Frias, Juan P', 'Kumar, Harish', 'Lausvig, Nanna L', 'le Roux, Carel W', 'Thielke, Desiree', 'Viljoen, Adie', 'McCrimmon, Rory J']
Journal Title : The lancet. Diabetes & endocrinology
Chapter : Section3
Journal Year : 2019
Cited by : Not Available

BACKGROUND: Existing guidelines for management of type 2 diabetes recommend a patient-centred approach to guide the choice of pharmacological agents. Although glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose cotransporter-2 (SGLT2) inh.....

Keywords : ["onceweekly semaglutide versus daily canagliflozin", "doubleblind phase randomise control trial", "type diabetes sustain", "safety", "patient", "metformin", "efficacy", "addon"]